Short-duration, Low-impact, High-intensity Osteogenic Loading for Postmenopausal Osteoporosis
Overview
This quasi-experimental study evaluated the effects of Osteostrong®, a brief weekly low-impact, high-intensity osteogenic loading system, on bone mineral density (BMD) and trabecular bone score (TBS) in peri- and postmenopausal women with osteoporosis over 12 months. Significant lumbar spine BMD improvements were observed in women receiving Osteostrong® combined with antiresorptive medication, while other BMD and TBS changes were not significant after adjustment. These findings suggest modest benefits warranting further randomized trials.
Background
Osteoporosis is a global health burden characterized by decreased BMD and disrupted bone microarchitecture, leading to increased fracture risk, especially in postmenopausal women. Standard diagnosis relies on DXA measurements of BMD at the lumbar spine, total hip, and femoral neck, with TBS providing additional insight into bone quality. While pharmacotherapy remains the mainstay of treatment, nonpharmaceutical interventions such as exercise are recommended but lack specific guidelines. Osteostrong® offers a novel, brief, low-impact, high-intensity osteogenic loading exercise system aimed at improving bone strength.
Data Highlights
Group
Intervention
Medication
Site
Mean Paired Change (g/cm2)
Bonferroni-adjusted p-value
G2
Osteostrong®
Yes
Lumbar Spine BMD
0.029
<0.001
G4
No Osteostrong®
Yes
Lumbar Spine BMD
0.025
0.05
G2
Osteostrong®
Yes
Total Hip BMD (Left)
0.028
0.05
Key Findings
Osteostrong® combined with antiresorptive medication (G2) significantly increased lumbar spine BMD by 0.029 g/cm2 (p < 0.001) over 12 months.
Women on antiresorptive medication without Osteostrong® (G4) showed a smaller but significant lumbar spine BMD increase of 0.025 g/cm2 (p = 0.05).
Total hip BMD (left) improved significantly in the Osteostrong® plus medication group (G2) by 0.028 g/cm2 (p = 0.05).
Other changes in femoral neck BMD, total hip BMD, and trabecular bone score (TBS) were not statistically significant after Bonferroni correction.
Osteostrong® intervention demonstrated modest bone density improvements, suggesting potential as an adjunct to pharmacotherapy.
Clinical Implications
The Osteostrong® system may offer a practical, brief, and low-impact exercise option to modestly improve lumbar spine BMD in postmenopausal women, especially when combined with antiresorptive medication. However, given the limited significant findings and the need for cautious interpretation, clinicians should consider Osteostrong® as a complementary approach pending further randomized controlled trials. Monitoring BMD at multiple skeletal sites remains important for comprehensive fracture risk assessment.
Conclusion
Osteostrong® shows promise in modestly enhancing lumbar spine BMD in postmenopausal osteoporosis over 12 months, particularly alongside antiresorptive therapy. Further rigorous randomized studies are needed to confirm efficacy and define its role in clinical practice.
References
Study Authors 2024 -- Short-duration, Low-impact, High-intensity Osteogenic Loading for Postmenopausal Osteoporosis
